Potential DNA Vaccine for Haemorrhagic Septiceamia Disease

Pasteurella multocida is the main cause of haemorrhagic septicaemia (HS) outbreak in livestock, such as cattle and buffaloes. Conventional vaccines such as alum-precipitated or oil-adjuvant broth bacterins were injected subcutaneously to provide protection against HS. However, the immunity developed...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biotechnology 2020-05, Vol.62 (5), p.289-296
Main Authors: Chelliah, Shamini, Velappan, Rita Devi, Lim, Kang Tzin, Swee, Chuan Wei Kelvin, Nor Rashid, Nurshamimi, Rothan, Hussin A., Kabir, Nurul, Ismail, Salmah
Format: Article
Language:English
Subjects:
Antibodies
Bacterins
Biochemistry
Biological Techniques
Biotechnology
Buffalo
Cell Biology
Cell lines
Chemistry
Chemistry and Materials Science
Cloning
Deoxyribonucleic acid
DNA
DNA vaccines
Enzyme-linked immunosorbent assay
Gene expression
Hemorrhagic septicemia
Human Genetics
Immunization
Immunogenicity
In vivo methods and tests
Livestock
Original Paper
Pasteurella multocida
Protein Science
Shotguns
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pasteurella multocida is the main cause of haemorrhagic septicaemia (HS) outbreak in livestock, such as cattle and buffaloes. Conventional vaccines such as alum-precipitated or oil-adjuvant broth bacterins were injected subcutaneously to provide protection against HS. However, the immunity developed is only for short term and needed to be administered frequently. In our previous study, a short gene fragment from Pasteurella multocida serotype B was obtained via shotgun cloning technique and later was cloned into bacterial expression system. pQE32-ABA392 was found to possess immunogenic activity towards HS when tested in vivo in rat model. In this study, the targeted gene fragment of ABA392 was sub-cloned into a DNA expression vector pVAX1 and named as pVAX1-ABA392. The new recombinant vaccine was stable and expressed on mammalian cell lines. Serum sample collected from a group of vaccinated rats for ELISA test shows that the antibody in immunized rats was present at high titer and can be tested as a vaccine candidate with challenge in further studies. This successful recombinant vaccine is immunogenic and potentially could be used as vaccine in future against HS.
ISSN:1073-6085
1559-0305
DOI:10.1007/s12033-020-00244-0